|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
Journal of Cell Science, Vol 114, Issue 5 909-916, Copyright © 2001 by Company of Biologists
JOURNAL ARTICLES |
C Iancu, SJ Mistry, S Arkin, S Wallenstein and GF Atweh
Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
Stathmin is a major cytosolic phosphoprotein that plays an important role in the regulation of microtubule dynamics during cell cycle progression. It has recently been proposed that the major function of stathmin is to promote depolymerization of the microtubules that make up the mitotic spindle. In this report, we tested the prediction that a deficiency in stathmin expression would result in constitutive stabilization of microtubules and lead to abnormalities in the organization of the mitotic spindle. Our studies demonstrate that antisense inhibition of stathmin expression in K562 erythroleukemic cells results in increased ratio of polymerized to depolymerized tubulin. These changes are associated with phenotypic abnormalities of the mitotic spindle and difficulty in completing mitosis. These studies also showed that inhibition of stathmin expression results in increased susceptibility of K562 leukemic cells to the pharmacological agents, like taxol, which are known to stabilize the mitotic spindle. In contrast, stathmin inhibition results in decreased sensitivity to vinblastine, an agent that destabilizes the mitotic spindle. Thus, our experimental findings are supportive of the model that stathmin is a microtubule-destabilizing factor that plays an important role in the regulation of the mitotic spindle. We also suggest a potential therapeutic approach for cancer based on the combination of stathmin inhibition with pharmacologic agents that stabilize the mitotic spindle.
This article has been cited by other articles:
![]() |
S. J. Mistry, A. Bank, and G. F. Atweh Synergistic Antiangiogenic Effects of Stathmin Inhibition and Taxol Exposure Mol. Cancer Res., August 1, 2007; 5(8): 773 - 782. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M.R. Bhat and V. Setaluri Microtubule-Associated Proteins as Targets in Cancer Chemotherapy Clin. Cancer Res., May 15, 2007; 13(10): 2849 - 2854. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Holmfeldt, K. Brannstrom, S. Stenmark, and M. Gullberg Aneugenic Activity of Op18/Stathmin Is Potentiated by the Somatic Q18->E Mutation in Leukemic Cells Mol. Biol. Cell, July 1, 2006; 17(7): 2921 - 2930. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Honnappa, W. Jahnke, J. Seelig, and M. O. Steinmetz Control of Intrinsically Disordered Stathmin by Multisite Phosphorylation J. Biol. Chem., June 9, 2006; 281(23): 16078 - 16083. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zahedi, M. P. Revelo, S. Barone, Z. Wang, K. Tehrani, D. P. Citron, J. J. Bissler, H. Rabb, and M. Soleimani Stathmin-deficient mice develop fibrosis and show delayed recovery from ischemic-reperfusion injury Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1559 - F1567. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. H. Ng, B. H. Lin, C. P. Lim, G. Huang, T. Zhang, V. Poli, and X. Cao Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin J. Cell Biol., January 17, 2006; 172(2): 245 - 257. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Barone, T. Okaya, S. Rudich, S. Petrovic, K. Tenrani, Z. Wang, K. Zahedi, R. A. Casero, A. B. Lentsch, and M. Soleimani Distinct and sequential upregulation of genes regulating cell growth and cell cycle progression during hepatic ischemia-reperfusion injury Am J Physiol Cell Physiol, October 1, 2005; 289(4): C826 - C835. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Giampietro, F. Luzzati, G. Gambarotta, P. Giacobini, E. Boda, A. Fasolo, and I. Perroteau Stathmin Expression Modulates Migratory Properties of GN-11 Neurons in Vitro Endocrinology, April 1, 2005; 146(4): 1825 - 1834. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zahedi, Z. Wang, S. Barone, K. Tehrani, N. Yokota, S. Petrovic, H. Rabb, and M. Soleimani Identification of stathmin as a novel marker of cell proliferation in the recovery phase of acute ischemic renal failure Am J Physiol Cell Physiol, May 1, 2004; 286(5): C1203 - C1211. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Alli, J. Bash-Babula, J.-M. Yang, and W. N. Hait Effect of Stathmin on the Sensitivity to Antimicrotubule Drugs in Human Breast Cancer Cancer Res., December 1, 2002; 62(23): 6864 - 6869. [Abstract] [Full Text] [PDF] |
||||